Chengwen Li

Dr. Chengwen Li


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
WSWenwei Shao
Wenwei Shao
LELauriel F. Earley
Lauriel F. Earley
ZCZheng Chai
Zheng Chai
XCXiaojing Chen
Xiaojing Chen
JSJunjiang Sun
Junjiang Sun
CLChengwen Li
Chengwen Li
Data from clinical trials for hemophilia B using adeno-associated virus (AAV) vectors have demonstrated decreased transgenic coagulation factor IX (hFIX) expression 6–10 weeks after administration of a high vector dose. While it is likely that capsid-specific cytotoxic T lymphocytes eliminate vector-transduced hepatocytes, thereby resulting in decreased hFIX, this observation is not intuitively consistent with restored hFIX levels following prednisone application. Although the innate immune response is immediately activated following AAV vector infection via TLR pathways, no studies exist regarding the role of the innate immune response at later time points after AAV vector transduction. Herein, activation of the innate immune response in cell lines, primary human hepatocytes, and hepatocytes in a human chimeric mouse model was observed at later time points following AAV vector transduction. Mechanistic analysis demonstrated that the double-stranded RNA (dsRNA) sensor MDA5 was necessary for innate immune response activation and that transient knockdown of MDA5, or MAVS, decreased IFN-β expression while increasing transgene production in AAV-transduced cells. These results both highlight the role of the dsRNA-triggered innate immune response in therapeutic transgene expression at later time points following AAV transduction and facilitate the execution of effective strategies to block the dsRNA innate immune response in future clinical trials.

1 September 2018 in Biomaterials
Verified
Journal Article
Closed access
XZXintao Zhang
Xintao Zhang
THTing He
Ting He
ZCZheng Chai
Zheng Chai
RSR. Jude Samulski
R. Jude Samulski
CLChengwen Li
Chengwen Li

1 September 2018 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
JSJunjiang Sun
Junjiang Sun
WSWenwei Shao
Wenwei Shao
XCXiaojing Chen
Xiaojing Chen
EMElizabeth P. Merricks
Elizabeth P. Merricks
LWLauren Wimsey
Lauren Wimsey
CLChengwen Li
Chengwen Li
Adeno-associated virus (AAV) vectors have been successfully applied in hemophilia clinical trials. However, this approach is limited to patients without AAV-neutralizing antibodies (NAbs). In this study, we explored the feasibility of AAV re-administration in hemophilia A dogs treated initially 8 years ago with AAV8.canine FVIII. After the re-administration in two NAb-negative dogs with AAV8 vectors carrying human factor VIII (hFVIII), along with the proteasome inhibitor bortezomib, we observed a phenotypic improvement in both dogs that persisted in one dog. Phenotypic improvement disappeared at 59 days after re-administration in the other dog, and specific cytotoxic T lymphocytes (CTLs) to the capsid were detected at day 17, but not to hFVIII. hFVIII inhibitors were observed at day 59 and gradually increased. Mechanistic studies demonstrated an increase in pro-inflammatory cytokines, a decrease in immunomodulatory cytokines, as well as lower Tregs after re-administration. These results suggest that hFVIII inhibitor development may contribute to the therapeutic failure via immune response activation. Interestingly, it takes about 30-50 days for AAV NAb titers to decrease by half. Collectively, this study suggests that re-administration of the same AAV serotype after long-term follow-up is feasible and that the study of AAV NAb kinetics will provide important information for predicating the efficacy of re-administration.

31 December 2021 in Biomaterials
Verified
Journal Article
Closed access
XZXintao Zhang
Xintao Zhang
ZCZheng Chai
Zheng Chai
ADAmanda Lee Dobbins
Amanda Lee Dobbins
MIMichelle Itano
Michelle Itano
CACharles Askew
Charles Askew
CLChengwen Li
Chengwen Li

1 December 2019 in Human Gene Therapy Clinical Development
Verified
Journal Article
Closed access
THTing He
Ting He
MIMichelle Itano
Michelle Itano
LELauriel F. Earley
Lauriel F. Earley
NHNikita E. Hall
Nikita E. Hall
NRNatallia Riddick
Natallia Riddick
CLChengwen Li
Chengwen Li
Adeno-associated virus (AAV) vectors have become an important tool for delivering therapeutic genes for a wide range of neurological diseases. AAV serotypes possess differential cellular tropism in the central nervous system. Although several AAV serotypes or mutants have been reported to transduce the brain efficiently, conflicting data occur across studies with the use of various rodent strains from different genetic backgrounds. Herein, we performed a systematic comparison of the brain transduction properties among five AAV serotypes (AAV2, 5, 7, 8, and 9) in two common rodent strains (C57BL/6J and FVB/N), following local intrastriatal injection of AAV vectors encoding enhanced green fluorescent protein (EGFP) driven by the CBh promoter. Important differences were found regarding overall cellular tropism and transduction efficiency, including contralateral transduction among the AAV serotypes and between the mouse strains. We have further found loss of NeuN-immunoreactivity and microglial activation from AAV transduction in the different mouse strains. The important strain-specific differences from our study suggest that the genetic background of the mouse may affect AAV serotype transduction properties in the brain. These data can provide valuable information about how to choose an effective AAV vector for clinical application and interpret the data obtained from preclinical studies and clinical trials.

1 September 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZCZheng Chai
Zheng Chai
JSJunjiang Sun
Junjiang Sun
KRKelly Michelle Rigsbee
Kelly Michelle Rigsbee
MWMei Wang
Mei Wang
RSRichard Jude Samulski
Richard Jude Samulski
CLChengwen Li
Chengwen Li